SoftBank Vision Fund Leads $1.1 Billion Financing of Roivant Sciences

Palo Alto – August 14, 2017 – Cooley advised SoftBank Vision Fund, which led a $1.1 billion equity investment in Roivant Sciences. This investment, which includes existing shareholder participation, is intended to accelerate the launch of new subsidiaries within and beyond the biopharma industry. An international Cooley team was led by Matthew Bartus, partner and co-chair of the firm’s global emerging companies practice.

“Roivant has attracted world-class talent in its pursuit of developing and commercializing drugs that target large unmet medical needs,” said Akshay Naheta, managing director of SoftBank Group International, in a news release. “We are impressed with the ambition and track record of the Roivant team and look forward to supporting them in the next step of their journey, as they look to effectively harness technology and leverage big data across all aspects of their business.”

Roivant, which was founded in 2014, is dedicated to transformative innovation in healthcare. Roivant focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. It partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.

The SoftBank Vision Fund invests globally in the businesses and technologies that will enable the next stage of the Information Revolution, and make tomorrow’s world leading businesses possible. It invests across all technology sectors and geographies, including computational biology, data-driven healthcare and technology-enabled pharmaceutical businesses.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.